DK2250498T3 - Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays - Google Patents

Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays

Info

Publication number
DK2250498T3
DK2250498T3 DK09715619.4T DK09715619T DK2250498T3 DK 2250498 T3 DK2250498 T3 DK 2250498T3 DK 09715619 T DK09715619 T DK 09715619T DK 2250498 T3 DK2250498 T3 DK 2250498T3
Authority
DK
Denmark
Prior art keywords
choices
antibody
pharmaceutical
breast cancer
cancer therapy
Prior art date
Application number
DK09715619.4T
Other languages
English (en)
Inventor
Jeanne Harvey
Phillip Kim
Xinjun Liu
Limin Liu
Robert Barham
Bruce Neri
Sharat Singh
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Application granted granted Critical
Publication of DK2250498T3 publication Critical patent/DK2250498T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK09715619.4T 2008-02-25 2009-02-24 Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays DK2250498T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3131908P 2008-02-25 2008-02-25
US10640408P 2008-10-17 2008-10-17
US10838408P 2008-10-24 2008-10-24
US11790808P 2008-11-25 2008-11-25
US14055808P 2008-12-23 2008-12-23
PCT/US2009/035013 WO2009108637A1 (en) 2008-02-25 2009-02-24 Drug selection for breast cancer therapy using antibody-based arrays

Publications (1)

Publication Number Publication Date
DK2250498T3 true DK2250498T3 (da) 2013-02-04

Family

ID=40599946

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09715619.4T DK2250498T3 (da) 2008-02-25 2009-02-24 Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays
DK12183659.7T DK2602623T3 (da) 2008-02-25 2009-02-24 Fremgangsmåde til detekteringen af intracellulært trunkerede receptorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12183659.7T DK2602623T3 (da) 2008-02-25 2009-02-24 Fremgangsmåde til detekteringen af intracellulært trunkerede receptorer

Country Status (13)

Country Link
US (4) US8163499B2 (da)
EP (3) EP2250498B1 (da)
JP (2) JP5414701B2 (da)
CN (2) CN102016581B (da)
AU (1) AU2009219437B2 (da)
CA (2) CA2716826C (da)
DK (2) DK2250498T3 (da)
ES (3) ES2553390T3 (da)
HK (2) HK1182441A1 (da)
IL (3) IL207637A (da)
MX (1) MX2010009140A (da)
NZ (3) NZ587420A (da)
WO (1) WO2009108637A1 (da)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557286T3 (es) * 2003-03-03 2016-01-25 Dyax Corp. Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
BRPI0813583A2 (pt) 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
PL2310011T3 (pl) 2008-06-17 2013-12-31 Wyeth Llc Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
GB2467691A (en) 2008-09-05 2010-08-11 Aueon Inc Methods for stratifying and annotating cancer drug treatment options
WO2010085845A1 (en) * 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
MX356593B (es) 2009-04-06 2018-06-05 Wyeth Llc Régimen de tratamiento que utiliza neratinib para cáncer de mama.
CA2761777A1 (en) 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
PT2473854T (pt) * 2009-06-23 2017-10-17 Fundação D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud Sistemas e métodos para tratar, diagnosticar e prever a resposta à terapia do cancro de mama
ES2627909T3 (es) * 2009-07-15 2017-08-01 Diatech Holdings, Inc. Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos
WO2011015920A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A highly efficient process of purification and production of recombinant trastuzumab
WO2011015921A1 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A highly efficient process of purification and production of recombinant cetuximab
WO2011034919A2 (en) * 2009-09-15 2011-03-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer
JP5819307B2 (ja) * 2009-10-20 2015-11-24 ネステク ソシエテ アノニム 発癌性融合タンパク質を検出するための近接媒介性アッセイ
RU2558931C2 (ru) * 2010-01-12 2015-08-10 Нестек С.А. Способы предсказания ответа трижды негативного рака молочной железы на терапию
US8338456B2 (en) 2010-01-13 2012-12-25 Wyeth Llc Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor
WO2012006421A2 (en) 2010-07-07 2012-01-12 The Regents Of The University Of Michigan Diagnosis and treatment of breast cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
EP2656077A1 (en) 2010-12-23 2013-10-30 Nestec S.A. Drug selection for malignant cancer therapy using antibody-based arrays
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US20140024539A1 (en) * 2011-02-02 2014-01-23 Translational Genomics Research Institute Biomarkers and methods of use thereof
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
RU2578848C2 (ru) 2011-02-17 2016-03-27 Нестек С.А. Устройство и способ выделения лейкоцитов и раковых клеток путем фильтрования
WO2012154253A1 (en) 2011-02-17 2012-11-15 Prometheus Laboratories Inc. ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFα DRUGS
EP2908132B8 (en) 2011-03-02 2019-06-12 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
AU2012240242A1 (en) * 2011-04-04 2013-10-10 Nestec S.A. Methods for predicting and improving the survival of gastric cancer patients
BR112013028808A2 (pt) 2011-05-10 2016-09-06 Nestec Sa métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada
WO2013026027A1 (en) 2011-08-18 2013-02-21 Nestec S.A. Compositions and methods for detecting allelic variants
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
ES2607649T3 (es) * 2011-11-04 2017-04-03 Invivis Sas Ensayo para biomarcadores predictivos de la eficacia antiestrogénica
JP2015505959A (ja) * 2011-12-05 2015-02-26 ネステク ソシエテ アノニム 癌を有する患者に治療を選択する方法
CN103157109A (zh) * 2011-12-12 2013-06-19 中国科学院生物物理研究所 Cd146及其抗体诊断和治疗三阴性乳腺癌的应用
EP2798085B1 (en) * 2011-12-30 2018-01-24 Quest Diagnostics Investments Incorporated Aptamers and diagnostic methods for detecting the egf receptor
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US20150212087A1 (en) * 2012-07-27 2015-07-30 Centre Leon Berard Detection of the ERalpha/Src/PI3K Complex as Predictive Marker in Breast Cancer
AU2013326070A1 (en) 2012-10-05 2015-04-23 Société des Produits Nestlé S.A. Methods for predicting and monitoring mucosal healing
CN113156139A (zh) * 2013-01-03 2021-07-23 梅索磅秤技术有限公司 测定实验对象组
EP2954328A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
EP2954329A1 (en) 2013-02-05 2015-12-16 Nestec S.A. Methods of selecting combination therapy for colorectal cancer patients
WO2014122582A1 (en) 2013-02-05 2014-08-14 Nestec S.A. Drug selection for non-small cell lung cancer therapy
CA2904181A1 (en) 2013-03-13 2014-10-09 Anahit Aghvanyan Sandwich immunoassay comprising anchoring reagent
US10114015B2 (en) 2013-03-13 2018-10-30 Meso Scale Technologies, Llc. Assay methods
JP6663347B2 (ja) * 2013-03-15 2020-03-11 ヤンセン ファーマシューティカ エヌ．ベー． 予測バイオマーカーのためのアッセイ
EP2984088B1 (en) * 2013-04-12 2019-03-20 Asana BioSciences, LLC Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
MX2015016065A (es) 2013-05-21 2016-03-21 Nestec Sa Metodos para predecir y mejorar la supervivencia de pacientes de cancer colorrectal.
EP3019867A1 (en) 2013-07-09 2016-05-18 Nestec S.A. Microfluidic collaborative enzyme enhanced reactive ceer immunoassay
EP3039429B1 (en) 2013-08-30 2018-10-10 Nestec S.A. Polyp recurrence
ES2729638T3 (es) * 2013-10-11 2019-11-05 Ventana Med Syst Inc Ensayos múltiplex de tinción conjunta de receptores de HER2 y de estrógenos para detectar heterogeneidad tumoral
US20160273045A1 (en) * 2013-10-23 2016-09-22 Oregon Health & Science University Methods of determining breast cancer prognosis
WO2015083085A1 (en) 2013-12-03 2015-06-11 Nestec S.A. Signaling pathways in tissues from inflammatory bowel disease patients
WO2015089380A2 (en) 2013-12-12 2015-06-18 Celcuity Llc Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent
US9730935B2 (en) * 2013-12-13 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
CN106574927A (zh) * 2014-01-14 2017-04-19 崔元哲 使用luterial的形态学特征筛选癌症预防剂或抗癌剂的方法
WO2015110989A1 (en) 2014-01-23 2015-07-30 Nestec S.A. Biomarker panel for assessment of mucosal healing
WO2015166461A1 (en) 2014-05-01 2015-11-05 Nestec S.A. Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels
JP6695280B2 (ja) 2014-05-15 2020-05-20 メソ スケール テクノロジーズ エルエルシー 改善されたアッセイ方法
CN104083762A (zh) * 2014-06-27 2014-10-08 中国科学院生物物理研究所 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途
EP3210016A1 (en) 2014-10-20 2017-08-30 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
MX2017006959A (es) 2014-12-02 2017-08-10 Nestec Sa Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable.
AU2015360260B2 (en) * 2014-12-12 2021-10-28 Celcuity Inc. Methods of measuring ErbB signaling pathway activity to diagnose and treat cancer patients
JP6720138B2 (ja) * 2015-03-13 2020-07-08 シスメックス株式会社 被検物質の検出方法およびその方法に用いられる試薬キット
US10724071B2 (en) 2015-10-14 2020-07-28 Nitto Boseki Co., Ltd. Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used
KR20190015360A (ko) * 2016-05-31 2019-02-13 네스텍 소시에테아노님 Ｈｅｒ2 및 ｈｅｒ3 경로 아형 분류를 기반으로 한, 유방암 환자에 대한 약물 치료법의 선택 방법
CN107727752B (zh) * 2016-08-12 2019-11-08 北大方正集团有限公司 免疫抑制剂依维莫司的分析方法
JP6779483B2 (ja) 2016-09-29 2020-11-04 住友ゴム工業株式会社 医療用検査装置及び細胞検査方法
JP6518985B2 (ja) 2016-09-29 2019-05-29 住友ゴム工業株式会社 がん細胞捕捉方法
CN106645728A (zh) * 2016-11-09 2017-05-10 百奥森（江苏）食品安全科技有限公司 一种食品中氟喹诺酮类药物的检测试剂盒
WO2018103834A1 (en) * 2016-12-07 2018-06-14 Fundació Privada Institut D'investigació Oncológica De Vall D'hebron Her2 as a predictor of response to dual her2 blockade in the absence of cytotoxic therapy
EP3879269A3 (en) 2017-03-20 2021-11-17 Celcuity Inc. Methods of measuring signaling pathway activity for selection of therapeutic agents
DK3612519T3 (da) 2017-04-18 2022-03-07 Lilly Co Eli Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
AU2018277256A1 (en) 2017-05-31 2020-01-30 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in Crohn's disease patients
JP7328960B2 (ja) 2017-10-10 2023-08-17 プロメテウス バイオサイエンシーズ インコーポレイテッド ベドリズマブ処置をモニタリングするための方法
JP7109719B2 (ja) 2018-02-14 2022-08-01 住友ゴム工業株式会社 特定細胞捕捉方法
JP7158671B2 (ja) 2018-02-14 2022-10-24 住友ゴム工業株式会社 特定細胞捕捉方法
CA3095156A1 (en) 2018-03-26 2019-10-03 Icahn School Of Medicine At Mount Sinai Methods of treating minimal residual cancer
US10871485B2 (en) 2018-04-13 2020-12-22 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
US11614440B2 (en) 2019-01-24 2023-03-28 Sumitomo Rubber Industries, Ltd. Specific cell fractionating and capturing methods
JP6886667B2 (ja) * 2019-03-27 2021-06-16 住友ゴム工業株式会社 がん細胞捕捉方法
AU2021327387A1 (en) 2020-08-21 2023-05-04 Genzyme Corporation Fgfr3 antibodies and methods of use
CN113929764B (zh) * 2021-10-15 2023-12-29 中山大学孙逸仙纪念医院 一种乳腺叶状肿瘤分子标志物cd146及其应用

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US5516931A (en) * 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4690890A (en) 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
SE8500817D0 (sv) 1985-02-20 1985-02-20 Lars Jonsson Halvoppet anestesisystem
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US4975532A (en) 1986-11-28 1990-12-04 Sclavo, Inc. Method to derivatize dextran
JPH01163661A (ja) 1987-10-02 1989-06-27 E I Du Pont De Nemours & Co ＩｇＧ捕捉抗体および多重単クローン性抗体検出系を用いたイムノアツセイ
US4855241A (en) * 1988-05-26 1989-08-08 Washington University Tumor diagnostic method
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5192660A (en) 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
US5089419A (en) 1989-08-07 1992-02-18 International Canine Genetics Detection of pregnancy by identification of the c peptide of relaxin in the urine of animals
US5120660A (en) 1989-12-05 1992-06-09 International Canine Genetics, Inc. Method for canine fertility detection
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
FR2672128B1 (fr) 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
JPH06109734A (ja) 1992-09-30 1994-04-22 S R L:Kk 抗原の測定方法
US6201109B1 (en) 1993-01-13 2001-03-13 Dade Behring Marburg Gmbh Assay for bone alkaline phosphatase
CA2170873A1 (en) 1993-09-03 1995-03-09 Dariush Davalian Fluorescent oxygen channeling immunoassays
JP3825815B2 (ja) 1994-01-31 2006-09-27 信義 清水 上皮細胞増殖因子レセプターに対するモノクローナル抗体の結合体ならびにその複合体およびその細胞への嵌入方法
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
FI98961C (fi) 1994-08-26 1997-09-10 Medix Biochemica Ab Oy Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5876944A (en) 1996-06-10 1999-03-02 Bayer Corporation Method for amplification of the response signal in a sandwich immunoassay
US6416967B2 (en) 1996-07-12 2002-07-09 Precision Therapeutics, Inc. Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
US5728541A (en) 1996-07-12 1998-03-17 Precision Therapeutics, Inc. Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays
US20040023375A1 (en) 2002-07-30 2004-02-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6780582B1 (en) 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6897073B2 (en) 1998-07-14 2005-05-24 Zyomyx, Inc. Non-specific binding resistant protein arrays and methods for making the same
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
RU2165081C2 (ru) 1999-01-05 2001-04-10 Ставропольский научно-исследовательский противочумный институт Способ индикации микроорганизмов
US6335173B1 (en) 1999-01-12 2002-01-01 Verve, Ltd. C/O James Bell Methods for detecting an analyte of interest using tyramide coating technology
GB9901072D0 (en) 1999-01-19 1999-03-10 Imp Cancer Res Tech Methods for detecting changes to a macromolecular component of a cell
US6972198B2 (en) 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
RU2149404C1 (ru) 1999-03-24 2000-05-20 Московский НИИ глазных болезней им. Гельмгольца Способ прогнозирования клинического течения увеальной меланомы
US6627400B1 (en) 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6649351B2 (en) 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
DE19926010C2 (de) 1999-06-08 2003-01-30 Bundesdruckerei Gmbh Wert- und Sicherheitsdokument mit Sicherheitsmerkmal mit Piezo-Effekt-basierten Eigenschaften und dazugehöriges Nachweisverfahren
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US7033781B1 (en) * 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
EP1224463A2 (en) * 1999-10-08 2002-07-24 Superarray, Inc. Compositions and methods for detecting protein modification and enzymatic activity
CA2385614A1 (en) 1999-10-13 2001-04-19 Timothy Johann Multiplex cytokine analysis
US7537938B2 (en) 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US6511809B2 (en) 2000-06-13 2003-01-28 E. I. Du Pont De Nemours And Company Method for the detection of an analyte by means of a nucleic acid reporter
AU2001277245A1 (en) 2000-08-03 2002-02-18 Massachusetts Institute Of Technology Microarrays of functional biomolecules, and uses therefor
ATE475887T1 (de) * 2000-09-09 2010-08-15 Univ New York State Res Found Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebses
US6797481B1 (en) 2000-10-17 2004-09-28 Dade Behring Marburg Gmbh Simultaneous screening of multiple analytes
US7635571B2 (en) 2000-12-07 2009-12-22 Siemens Healthcare Diagnostics Products Gmbh Amplified signal in binding assays
DE10064827A1 (de) 2000-12-22 2002-06-27 Dade Behring Marburg Gmbh Nachweisverfahren
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20020168641A1 (en) 2001-03-09 2002-11-14 Bruce Mortensen Fluorescein-cyanine 5 as a fluorescence resonance energy transfer pair
US20020142361A1 (en) 2001-03-27 2002-10-03 Emmert-Buck Michael R. Biodetection method
WO2002084252A2 (en) 2001-04-17 2002-10-24 Xenoport, Inc. Epitope-captured antibody display
WO2002090964A1 (en) 2001-05-03 2002-11-14 Genometrix Genomics, Inc. Method and apparatus to determine the performance of protein arrays
WO2002103321A2 (en) 2001-06-14 2002-12-27 Anadys Pharmaceuticals, Inc. Methods of screening for ligands of target molecules
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US20060269548A1 (en) 2001-07-12 2006-11-30 Kari Alitalo Lymphatic endothelial cells materials and methods
JP2003028874A (ja) * 2001-07-12 2003-01-29 Mitsubishi Chemicals Corp ２段階酵素反応を用いた測定対象物質の測定法
US8323903B2 (en) 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
US20030087311A1 (en) 2001-11-07 2003-05-08 Wolf David E. Method of identifying energy transfer sensors for analytes
AU2003222253A1 (en) 2002-03-05 2003-09-22 Monogram Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
WO2003087761A2 (en) * 2002-04-05 2003-10-23 Cell Signaling Technology, Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040229380A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
ES2376165T3 (es) 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
FR2843126B1 (fr) 2002-08-01 2006-01-27 Cis Bio Int "methode de determination d'une activite enzymatique endoglycosidase"
US20040235002A1 (en) 2002-09-20 2004-11-25 Sangamo Biosciences, Inc. Multiplex screening assays
US20030153013A1 (en) 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
WO2004053497A2 (en) * 2002-12-11 2004-06-24 Ventana Medical Systems, Inc. Method for predicting the response to her2-directed therapy
WO2004071572A2 (en) 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
EP1613961A4 (en) 2003-04-01 2007-03-07 Monogram Biosciences Inc SURFACE RECEPTOR COMPLEXES AS BIOMARKERS
US20040265938A1 (en) 2003-06-25 2004-12-30 Jose Remacle Method for the determination of cell activation
US7279286B2 (en) 2003-09-11 2007-10-09 Sanofi-Aventis Deutschland Gmbh High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity
FI20031370A0 (fi) 2003-09-23 2003-09-23 Wallac Oy Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan
EP1681983A4 (en) 2003-10-14 2008-12-10 Monogram Biosciences Inc RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY
DE602004026341D1 (de) 2003-11-04 2010-05-12 Bayer Pharmaceuticals Corp IMMUNOHISTOCHEMISCHE VERFAHREN ZUR ÜBERWACHUNG VON pERK SPIEGELN
CA2548394A1 (en) * 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
CA2559803A1 (en) 2004-03-03 2005-10-13 Bayer Technology Services Gmbh Analytical platform and method for generating protein expression profiles of cell populations
EP1751309B1 (en) 2004-05-27 2015-07-22 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20060263837A1 (en) 2004-06-17 2006-11-23 Liu George D Immunoassay system and method for detection of antigens
WO2006026020A2 (en) 2004-07-30 2006-03-09 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
WO2006031815A2 (en) 2004-09-13 2006-03-23 Monogram Biosciences, Inc. Methods and compositions for proximity assays
US20080254497A1 (en) * 2004-10-15 2008-10-16 Monogram Biosciences, Inc. Response Predictors for Erbb Pathway-Specific Drugs
WO2006045991A1 (en) 2004-10-25 2006-05-04 Astrazeneca Ab Method to predict whether a tumor will react to a chemotherapeutic treatment
WO2006054991A1 (en) 2004-11-17 2006-05-26 Immunivest Corporation Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection
WO2006055739A2 (en) 2004-11-17 2006-05-26 Robert Sack Stationary phase antibody arrays for trace protein analysis
DE102004056794B4 (de) 2004-11-24 2010-08-26 Protagen Ag Verwendung einer Anordnung und Verfahren zur Validierung von Bindern
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
JP4851730B2 (ja) * 2005-05-09 2012-01-11 小澤 滿 除塵加湿装置
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
US7771955B2 (en) 2005-06-09 2010-08-10 University Of Maryland Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
JP2007089548A (ja) * 2005-09-30 2007-04-12 Univ Of Tokushima シグナル増幅方法
CN101008644A (zh) * 2006-01-27 2007-08-01 陈云 功能性中枢神经损伤诊断检测用蛋白芯片及其制造方法
JP5048757B2 (ja) * 2006-05-05 2012-10-17 イェール・ユニバーシティー 診断指標または予測指標としての細胞内局在プロフィールの使用
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures
CN104198705B (zh) 2006-09-21 2017-06-09 雀巢产品技术援助有限公司 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
AU2007333468A1 (en) * 2006-10-23 2008-06-19 The Uab Research Foundation Biomarkers for cancer sensitivity to an anti-cancer agent and uses thereof
AU2007317204A1 (en) 2006-11-10 2008-05-15 Dimerix Bioscience Pty Ltd Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers
EP2518508A1 (en) 2006-11-28 2012-10-31 U3 Pharma GmbH Activated HER3 as a marker for predicting therapeutic efficacy
WO2008117278A2 (en) 2007-03-27 2008-10-02 Rosetta Genomics Ltd. Gene expression signature for classification of cancers
JP2008292424A (ja) 2007-05-28 2008-12-04 Nippon Medical School 腫瘍の検出方法
BRPI0813583A2 (pt) 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
EP2065475A1 (en) 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
ES2627909T3 (es) 2009-07-15 2017-08-01 Diatech Holdings, Inc. Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos
US20120270745A1 (en) 2009-07-15 2012-10-25 Prometheus Laboratories Inc. Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples
WO2012047294A2 (en) 2010-10-06 2012-04-12 Ludwig Institute For Cancer Research Ltd Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US20120231965A1 (en) 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
US20130216523A1 (en) 2011-03-31 2013-08-22 Laboratory Corporation Of America Holdings Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링

Also Published As

Publication number Publication date
ES2545760T3 (es) 2015-09-15
IL225241A (en) 2015-04-30
ES2398618T3 (es) 2013-03-20
US20100167945A1 (en) 2010-07-01
CA2923248A1 (en) 2009-09-03
CN103399144A (zh) 2013-11-20
EP2602623B1 (en) 2015-09-16
CN102016581B (zh) 2014-07-30
JP5414701B2 (ja) 2014-02-12
MX2010009140A (es) 2010-12-20
JP2013174616A (ja) 2013-09-05
AU2009219437A1 (en) 2009-09-03
JP5852047B2 (ja) 2016-02-03
IL222872A (en) 2014-11-30
US20140349865A1 (en) 2014-11-27
US8163499B2 (en) 2012-04-24
JP2011514522A (ja) 2011-05-06
EP2250498A1 (en) 2010-11-17
ES2553390T3 (es) 2015-12-09
NZ600339A (en) 2013-12-20
IL207637A (en) 2013-04-30
DK2602623T3 (da) 2015-11-09
US20130045880A1 (en) 2013-02-21
CA2716826C (en) 2017-05-09
IL222872A0 (en) 2012-12-31
CA2716826A1 (en) 2009-09-03
HK1182441A1 (zh) 2013-11-29
US9274116B2 (en) 2016-03-01
EP2602623A3 (en) 2013-10-16
CN102016581A (zh) 2011-04-13
EP2618146A3 (en) 2013-11-06
EP2618146A2 (en) 2013-07-24
HK1185414A1 (en) 2014-02-14
US20160123984A1 (en) 2016-05-05
NZ587420A (en) 2012-07-27
WO2009108637A1 (en) 2009-09-03
EP2618146B1 (en) 2015-06-17
US8609349B2 (en) 2013-12-17
IL207637A0 (en) 2010-12-30
EP2602623A2 (en) 2013-06-12
AU2009219437B2 (en) 2014-10-16
CN103399144B (zh) 2015-10-28
US10436786B2 (en) 2019-10-08
EP2250498B1 (en) 2012-10-31
NZ617520A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
DK2250498T3 (da) Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays
EP2454598A4 (en) ACTIVE SUBSTANCE SELECTION FOR ANTIBODY ARRAYS
IL227009B (en) Drug selection for malignant cancer therapy using antibody-based arrays
DK3401334T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK2121139T3 (da) Formulations for cancer treatment
ZA201000310B (en) Drug selection for lung cancer therapy using antibody-based arrays
BRPI1006438A2 (pt) terapia adjuvante de cancer
DK2346552T4 (da) Lægemiddelafgivelsesanordning og fremgangsmåde til fremstilling af en lægemiddelafgivelsesanordning
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2076289T3 (da) Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider
DK3192529T3 (da) Amatoksin-holdige terapeutiske celleoverflade-bindingskomponenter designet til tumorterapi
BRPI0810206A2 (pt) Método de tratar câncer
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
BR112012005594A2 (pt) tratamento de câncer
DE602009000539D1 (de) Strahlentherapiegerät
ATE478053T1 (de) Neuartige verbindungen
DE602008000456D1 (de) Strahlentherapievorrichtung
BRPI0918178A2 (pt) anticorpos monoclonais para tratamento de câncer
DK2162149T3 (da) Vaccine til forebyggelse af brystkræfttilbagefald
DK2440230T3 (da) Behandlingsregimener til behandling af neurologisk sygdom
DK3106875T3 (da) Fremgangsmåde til detektering af cancer
BR112012002797A2 (pt) tratamento de câncer de próstata
BRPI0918064A2 (pt) distribuidor de substância
DK3276004T3 (da) Fremgangsmåder til behandling af kronisk nyresygdom
BRPI0820410A2 (pt) Lactans substituídos terapêuticos